G. Başaran Et Al. , "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey," American Society of Clinical Oncology (ASCO) Annual Meeting , Illinois, United States Of America, pp.13055, 2020
Başaran, G. Et Al. 2020. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey. American Society of Clinical Oncology (ASCO) Annual Meeting , (Illinois, United States Of America), 13055.
Başaran, G., Demirci, U., Yıldız, F., Çiçin, İ., Aktaş, B. Y., Öztürk, B., ... Sezgin Göksu, S.(2020). Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey . American Society of Clinical Oncology (ASCO) Annual Meeting (pp.13055). Illinois, United States Of America
Başaran, Gül Et Al. "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey," American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 2020
Başaran, Gül Et Al. "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey." American Society of Clinical Oncology (ASCO) Annual Meeting , Illinois, United States Of America, pp.13055, 2020
Başaran, G. Et Al. (2020) . "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey." American Society of Clinical Oncology (ASCO) Annual Meeting , Illinois, United States Of America, p.13055.
@conferencepaper{conferencepaper, author={Gül BAŞARAN Et Al. }, title={Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey}, congress name={American Society of Clinical Oncology (ASCO) Annual Meeting}, city={Illinois}, country={United States Of America}, year={2020}, pages={13055} }